298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2

A-Alpha Bio's new data consortium aims to multiply public antibody affinity data 200x+ by pooling prospective, pre-competitive experiments across pharma and AI labs.

• Data consortium launched: A-Alpha Bio's five founding members each receive ~28M affinity measurements/year, versus only ~500,000 total antibody affinity measurements publicly available today.
• A-Alpha Bio dominates public data: Younger estimates upwards of 75% of all public antibody affinity data originates from his company's own AlphaSeq publications.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.